The human insulin analogue insulin lispro

References

• Barnett A H, Owens D R. Insulin analogues. Lancet 1997; 349: 47–51
   PubMed Web of Science ®Google Scholar
• Holleman F, Hoekstra J BL. Insulin lispro. N Engl J Med 1997; 337: 176–83
   PubMed Web of Science ®Google Scholar
• Howey D C, Bowsher R R, Brunelle R L, Woodworth J R. [Lys(B28), Pro(B29)l-human insulin. A rapidly absorbed analog of human insulin. Diabetes 1994; 43: 396–402
   PubMed Web of Science ®Google Scholar
• terBraak E W, Woodworth J R, Bianchi R, et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996; 19: 1437–40
   PubMed Web of Science ®Google Scholar
• Anderson JH, Jr., Brunelle R L, Koivisto V A, Trautmann M E, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Ther 1997; 19: 62–72
   PubMed Web of Science ®Google Scholar
• Anderson JH, Jr, Brunelle R L, Koivisto V A, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997; 46: 265–70
   PubMed Web of Science ®Google Scholar
• Anderson JH, Jr, Brunelle R, Keohane P, et al. Insulin analogue improves mealtime treatment of NIDDM patients. Arch Intern Med 1997; 157: 1249–55
   PubMed Web of Science ®Google Scholar
• Holcombe J, Zalani S, Arora V. Comparative study of insulin lispro and regular human insulin in 481 adolescents with type 1 diabetes. Diabetologia 1997; 40(Suppl 1)A344
   PubMedGoogle Scholar
• Zinman B, Tildesley H, Chiasson J L, Tsui E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997; 46: 440–3
   PubMed Web of Science ®Google Scholar
• El-Ghazali S, Akram J, Al-Maatouq M. Management of diabetes mellitus during the holy month of Ramadan. Proceedings of an International Symposium. Practical Diabetes International 1998; 15: S17–S20
   Google Scholar
• Burge M R, Castillo K R, Schade D S. Meal composition is a determinant of lispro induced hypoglycemia in IDDM. Diabetes Care 1997; 20: 152–5
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Wein W, Sandholzer K, Equiliz-Bruck S, Bates P C, Birkett M A. Postprandial insulin lispro: a new therapeutic option for type 1 diabetic patients. Diabetes Care 1998; 21: 570–3
   PubMed Web of Science ®Google Scholar
• Holleman F, van den Brand J JG, Hoven R AR, et al. Comparison of Lys B28, ProB29-human insulin analog and regular human insulin in the correction of incidental hyperglycemia. Diabetes Care 1996; 19: 1426–9
   PubMed Web of Science ®Google Scholar
• Hanaire H, Bringer J, Lassmann-Vague V, et al. Improvement of HbAiewithout increasing hypoglycemia risk in diabetic patients treated with insulin lispro in external pumps. Diabetologia 1997; 40(Suppl 1)A10
   Google Scholar
• Ebeling P, Jansson P A, Smith U, Lalli C, Bolli G B, Koivisto V A. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin. Diabetes Care 1997; 20: 1287–9
   PubMed Web of Science ®Google Scholar
• Ebeling P, Jansson P-A, Smith U, et al. Optimal combination of insulin lispro and basal insulin improves glycemic control in IDDM. Diabetologia 1997; 40(Suppl 1)A351
   Google Scholar
• Zinman B, Ross S, Campos R, Strack T. A double blind randomized controlled trial comparing NPH and Ultralente as basal insulin replacement with lispro insulin. The Canadian Lispro Study Group. Diabetes 1997; 46(Suppl 1)43A
   Google Scholar
• Bastyr EJ, III, Holcombe J, Anderson J H, Clore J N. Mixing insulin lispro with ultralente insulin. Diabetes Care 1997; 20: 1047–8
   PubMed Web of Science ®Google Scholar
• Feinglos M N, Thacker C H, English J, Bethel M A, Lane J. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997; 20: 1539–42
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The absence of glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289–98
   PubMed Web of Science ®Google Scholar
• Torlone E, Fanelli C, Rambotti A M, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 1994; 37: 713–20
   PubMed Web of Science ®Google Scholar
• Frier B M. Symptomatic and physiological responses to hypoglycaemia induced by human soluble insulin and the insulin analogue lispro human insulin. Diabet Med 1997; 14: 929–36
   PubMed Web of Science ®Google Scholar
• Brunelle R L, Llewelyn J, Vignati L, Anderson J, Koivisto V A. Humalog reduces the incidence of severe hypoglycemia in IDDM patients. Diabetologia 1997; 40(Suppl 1)A352
   PubMedGoogle Scholar
• Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson J H. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 1997; 20: 1827–32
   PubMed Web of Science ®Google Scholar
• Tuominen J A, Karonen S L, Melamies L, Bolli G, Koivisto V A. Exercise-induced hypoglycemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia 1995; 38: 106–11
   PubMed Web of Science ®Google Scholar
• Ronnemaa T, Viikari J. Reduction of snacks when switching IDDM patients from regular insulin to lispro insulin. Diabetologia 1997; 40(Suppl 1)A350
   Google Scholar
• Fineberg N S, Fineberg S E, Anderson J H, Birkett M A, Gibson R G, Hufferd S. Immunologic effects of insulin lispro [Lys(B28), Pro(B29) human insulin) in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996; 45: 1750–4
   PubMed Web of Science ®Google Scholar
• Lahtela J T, Knip M, Paul R, Antonen J, Salmi J. Severe insulin antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. Diabetes Care 1997; 20: 71–3
   PubMed Web of Science ®Google Scholar
• Henrichs H R, Unger H, Trautmann M E, Pfützer A. Severe insulin resistance treated with insulin lispro. Lancet 1996; 348: 1248
   PubMed Web of Science ®Google Scholar
• Kumar D. Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care 1997; 20: 1357–9
   PubMed Web of Science ®Google Scholar
• Diamond T, Kormas N. Possible adverse fetal effect of insulin lispro. N Engl J Med 1997; 337: 1009
   PubMed Web of Science ®Google Scholar
• Kotsanos J G, Vignati L, Huster W, et al. Health-related quality of life results from multinational clinical trials of insulin lispro. Diabetes Care 1997; 20: 948–58
   PubMed Web of Science ®Google Scholar